Lexicon Pharmaceuticals | LXRX - Current Liabilities


Lexicon Pharmaceuticals reported $20.87M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Abbott USD 16.5B 1.91B Dec/2025
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Akebia Therapeutics USD 162.94M 29.56M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Illumina USD 1.59B 377M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ironwood Pharmaceuticals USD 242.5M 9.98M Sep/2025
J&J USD 54.13B 3.26B Dec/2025
Lexicon Pharmaceuticals USD 20.87M 853K Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
MannKind USD 171.03M 61.9M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Thermo Fisher Scientific USD 15.19B 301M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025